💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Soligenix up 83% ahead of ricin vaccine data presentation

Published 04/19/2017, 10:31 AM
© Reuters.  Soligenix up 83% ahead of ricin vaccine data presentation
SNGX
-
  • Thinly traded nano cap Soligenix (SNGX +82.9%) jumps on a whopping 111x spike in volume ahead of a presentation next week on RiVax, its ricin toxin vaccine, at the 20th Annual Conference on Vaccine Research in Bethesda, MD. NY State Department of Health's Jennifer Yates, Ph.D., will be the presenter.
  • In preclinical testing, RiVax, formulated with the company's ThermoVax heat stabilization technology, demonstrated 100% protection in ricin aerosol challenge models.
  • The company says the data should support the FDA approval of RiVax under the "Animal Rule" which allows regulatory approval of certain drugs and biologics based on animal testing in situations where human testing is not possible or ethical.


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.